Serum Helicobacter pylori NapA antibody as a potential biomarker for gastric cancer

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Liu, Jingjing ^a   Liu, Huimin ^a   Zhang, Tingting ^a   Ren, Xiyun ^a   Nadolny, Christina ^b   Dong, Xiaoqun ^b   Huang, Lina ^a   Yuan, Kexin ^a   Tian, Wenjing ^a   Jia, Yunhe ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL PROTEIN; NEUTROPHIL-ACTIVATING PROTEIN A, HELICOBACTER PYLORI; TUMOR MARKER;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; BACTERIAL PROTEINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922597238     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04143     Document Type: Article

References (34)

1. Hamilton, J. P. & Meltzer, S. J. A review of the genomics of gastric cancer. Clin. Gastroenterol. Hepatol. 4, 416-425 (2006).
2. Conteduca, V. et al. H. pylori infection and gastric cancer: state of the art (review). Int. J. Oncol. 42, 5-18 (2013).
3. Yang, X. X. et al. Association of genetic polymorphisms at 1q22 but not 10q23 with gastric cancer in a southern Chinese population. Asian Pac. J. Cancer Prev. 13, 2519-2522 (2012).
4. Thiel, A. & Ristimaki, A. Gastric cancer: basic aspects. Helicobacter. 17 Suppl 1, 26-29 (2012).
5. Kim, S. S., Ruiz, V. E., Carroll, J. D. & Moss, S. F. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett. 305, 228-238 (2011).
6. Dundon, W. G. et al. The neutrophil-activating protein of Helicobacter pylori. Int. J. Med. Microbiol. 291, 545-550 (2002).
7. Lamb, A. & Chen, L. F. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J. Cell. Biochem. 114, 491-497 (2013).
8. Fuccio, L. et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 151, 121-128 (2009).
9. Chong, P. K. et al. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics. 10, 3210-3221 (2010).
10. Lam, K.W. & Lo, S. C. Discovery of diagnostic serum biomarkers of gastric cancer using proteomics. Proteomics Clin Appl. 2, 219-228 (2008).
11. Wen, S. & Moss, S. F. Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer lett. 282, 1-8 (2009).
12. Abdullah, S.M. et al. Infection with Helicobacter pylori strains carrying babA2 and cagA is associated with an increased risk of peptic ulcer disease development in Iraq. Arab J Gastroenterol. 13, 166-169 (2012).
13. D'Elios, M. M., Amedei, A., Cappon, A., Del Prete, G. & de Bernard, M. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol. Med. Microbiol. 50, 157-164 (2007).
14. Wang, C. A., Liu, Y. C., Du, S. Y., Lin, C. W. & Fu, H. W. Helicobacter pylorineutrophil-activating protein promotes myeloperoxidase release from human neutrophils. Biochem. Biophys. Res. Commun. 377, 52-56 (2008).
15. Pounder, R. E.&Ng, D. The prevalence of Helicobacter pylori infection in different countries. Aliment. Pharrnacol. Ther. 9, 33-39 (1995).
16. Asaka, M., Kato, M. & Graham, D. Y. Prevention of Gastric Cancer by Helicobacter pylori eradication. Intern. Med. 49, 633-636 (2010).
17. Wong, B. C. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 291, 187-194 (2004).
18. Prinz, C., Schwendy, S. & Voland, P. Helicobacter pylori and gastric cancer: shifting the global burden. World J. Gastroenterol. 12, 5458-5464 (2006).
19. Zhang, D. H. et al. Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin. Med. J. 122, 1759-1763 (2009).
20. Lee, W. J. et al. Clinicopathologic characteristics of Helicobacter pyloric seropositive gastric adenocarcinomas. J. Clin. Gastroenterol. 21, 203-207 (1995).
21. Gao, L. et al. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res. 69, 6164-6170 (2009).
22. Syrios, J. et al. Survival in patients with stage IV noncardia gastric cancer-the influence of DNA ploidy and Helicobacter pylori infection. BMC cancer. 12, 264 (2012).
23. Barreto-Zuñiga, R. et al. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J. Gastroenterol. 32, 289-294 (1997).
24. Gonzalez, C. A. et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast- EPIC project. Ann. Oncol. 23, 1320-1324 (2012).
25. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 49, 347-353 (2001).
26. Kamangar, F. et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J. Natl. Cancer Inst. 98, 1445-1452 (2006).
27. Kountouras, J. et al. Potential implications of Helicobacter pylori-related neutrophil-activating protein. World J. Gastroenterol. 18, 489-490 (2012).
28. Choli-Papadopoulou, T., Kottakis, F., Papadopoulos, G. & Pendas, S. Helicobacter pylori neutrophil activating protein as target for new drugs against H. pylori inflammation. World J. Gastroenterol. 17, 2585-2591 (2011).
29. Long, M., Luo, J., Li, Y., Zeng, F. Y.&Li, M. Detection and evaluation of antibodies against neutrophil-activating protein of Helicobacter pylori in patients with gastric cancer. World J. Gastroenterol. 15, 2381-2388 (2009).
30. Luo, J. et al. Clone, expression and immunoreaction of napA gene of Helicobacter pylori. Chin J Cell Mol Immunol. 23, 395-398 (2007).
31. Ohkusu, K. Cost-effective and rapid presumptive identification of gram-negative bacilli in routine urine, pus, and stool cultures: evaluation of the use of CHROMagar orientation medium in conjunction with simple biochemical tests. J. Clin. Microbiol. 38, 4586-4592 (2000).
32. Xiang, Z. et al. Detection in an enzyme immunoassay of an immune response to a recombinant fragment of the 128 kilodalton protein (CagA) of Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 12, 739-745 (1993).
33. Kashyap, R. S. et al. Diagnosis of tuberculosis in an Indian population by an indirect ELISA protocol based on detection of Antigen 85 complex: a prospective cohort study. BMC Infect. Dis. 7, 74 (2007).
34. Tang, J. W. et al. Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. J. Clin. Virol. 40, 284-288 (2007).